



Understanding stroke risk in patients with AFib



Every hour, 15 people with AFib will suffer a stroke¹. Of those:

- 3 won't walk without assistance
- 3 will have to go into nursing homes
- 4 will die



5x

increased risk of stroke for AFib patients²



of AFib-related strokes result in death or permanent disability³

795,000 total strokes

610,000 first or new strokes

Every year, more than

795,000

people in the United States have a stroke.

About

610,000

of these are first or new strokes.¹



AFib increases the risk of an embolic ischemic stroke. About **87% of all strokes are ischemic strokes**, in which blood flow to the brain is blocked.^{5,1}



Research suggests LAAC treatment may result in **less disabling and fatal ischemic strokes** at discharge and follow-up compared to DOACs.⁴

2x

For patients with AFib, risks of 1-year disability and 1-year mortality after stroke are **twice those of non-AFib-related strokes**.



Hospital stays are longer; acute and **long-term costs are higher**.^{6,7}



In non-valvular AFib, more than

90%


of stroke-causing clots that come from the heart are **formed in the left atrial appendage (LAA)**.⁸



The WATCHMAN Left Atrial Appendage Closure (LAAC) Implant is a **one-time, minimally invasive procedure** designed to reduce the risk of strokes that originate in the LAA.

The WATCHMAN LAAC Implant reduces the risk of stroke in non-valvular AFib patients

This analysis demonstrates the consistent performance of LAA closure with the WATCHMAN device in preventing ischemic stroke across the various clinical trials and real world experience, and across a range of patients with different baseline risk. Ischemic stroke rates are comparable to patients on anticoagulation with similar baseline characteristics.



Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

* Patients treated with anticoagulation were managed with Warfarin.

Note: Data from ASAP, WASP and EWOLUTION includes patients currently contraindicated for LAAC with WATCHMAN in the United States.

References: Friberg et al. *Eur Heart J* 2012;33(12):1500-1510 (Untreated Patients); National Institute for Health and Care Excellence. *Atrial fibrillation: medicines to help reduce your risk of a stroke – what are the options?* June 2014. Downloaded from guidance.nice.org.uk/CG180/PatientDecisionAid/pdf/English (Treated Patients). Reddy VY, et al. *JACC* 2017; 70(24): 2964–2975 (PROTECT AF and PREVAIL). Holmes, DR et al. *JACC* 2019; In Press (CAP and CAP2). Phillips KP et al. *ILC Heart & Vasculature* 2019; 23(100358) (WASP). Boersma LVA et al. *Circulation: Arrhythmia and Electrophysiology*. 2019; 12(4) : e006841. (EWOLUTION). Sharma D et al. *JACC* 2016; 67(18): 2190–2192 (ASAP). Late Breaking Clinical Trial at CRT 2023, Presented by Samir Kapadia. (SURPASS). Late Breaking Clinical Trial at AHA 2024, Presented by Oussama Wazni. (OPTION). SK Doshi et al. *Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation*. *New England Journal of Medicine*, March 2026. (CHAMPION-AF)

See which of your AFib patients may benefit from the WATCHMAN Implant at watchman.com/hcp.



One Time. For a Lifetime.



WATCHMAN FLX™ Pro LAAC Referrer
Indications, Safety and Warnings

<https://www.watchman.com/en-us-hcp/watchman-flx-pro-brief-summary.html>

References

1. Tsao CW, Aday AW, Almarazooq ZI, Beaton AZ, Bittencourt MS, Boehme AK, et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. *Circulation*. 2023;147:e93–e621.
2. Holmes DR, Atrial Fibrillation and Stroke Management: Present and Future, *Seminars in Neurology* 2010;30:528–536
3. Kelly-Hayes et al. *Journal of Stroke and Cerebrovascular Diseases* 12.3 (2003): 119–126.
4. Turagam, MK et al. Severity of Ischemic Stroke After Left Atrial Appendage Closure vs Nonwarfarin Oral Anticoagulants, *JACC: Clinical Electrophysiology*, 2023.
5. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. *Circulation*. 2014;129(8):837-847. doi:10.1161/CIRCULATIONAHA.113.005119
6. Ali AN, Abdelhafiz A. Clinical and economic implications of AF related stroke. *J Atr Fibrillation*. 2016; 8:1279. doi: 10.4022/jafb.1279
7. Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? *Neuroepidemiology*. 2013; 40:227–239. doi: 10.1159/000343667
8. Blackshear JL, Odell JA. *Annals of Thoracic Surg*. 1996; 61: 755–759.